Skip to main content
Arterra Bioscience logo

Arterra Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · IT0005386369 LEI · 8156006E67B9AB95E292 XMIL Manufacturing
Open in API
Filings indexed 113 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country IT Italy
Listing XMIL ABS

About Arterra Bioscience

https://arterrabio.it/en/

Arterra Bioscience is a biotechnology company focused on the research, development, and production of innovative ingredients and natural solutions. The company develops high-value-added active ingredients derived from natural sources through sustainable biotechnologies. Its core technological platforms include in vitro bioassays, plant cell cultures, in vitro and ex vivo models of skin and intestine, and recombinant protein production. The production process utilizes techniques like freeze-drying to create stable, preservative-free raw materials. These products are applied across various industrial sectors, including cosmetics, nutraceuticals, pharmaceuticals, agriculture, food, and medical devices.

Recent filings

Filing Released Lang Actions
ARTERRA BIOSCIENCE S.P.A.: FATTURATO AL 31 MARZO 2026 PARI A 1,6 MILIONI DI EURO
Regulatory Filings
2026-05-06 Italian
ARTERRA - ASSEMBLEA ORDINARIA DEGLI AZIONISTI
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a press release summarizing the resolutions passed at the ordinary shareholders’ meeting (approval of the 2025 financial statements, allocation of profit/dividend, and appointment of the auditor). It reports the outcomes of votes at the AGM, rather than containing the full annual report or simply announcing its publication. This aligns with the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-04-29 Italian
ARTERRA - FINANZIAMENTO E CONCESSIONE AGEVOLAZIONI PER IL PROGETTO “RE-FOOD”
Capital/Financing Update Classification · 1% confidence The document is a press release (“Comunicato Stampa”) by Arterra Bioscience announcing that its “Re‐Food” project received €720,012 of eligible costs and a €462,009.12 grant from the Italian Ministry under a public funding notice. It is an update on obtaining new financing and subsidies (not a share issuance, earnings, or regulatory notice), matching the “Capital/Financing Update” category.
2026-04-21 Italian
ARTERRA - PUBBLICAZIONE AVVISO DI CONVOCAZIONE DI ASSEMBLEA ORDINARIA
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a press release announcing the publication of the notice of convocation for the ordinary shareholders’ meeting, including the date, agenda items (approval of the annual financial statements, dividend distribution, auditor appointment), and participation instructions. This is a materials sent to shareholders to provide information and request their votes at the meeting, fitting the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-09 Italian
ARTERRA PARTECIPA ALLA “SPRING INVESTOR CONFERENCE” ORGANIZZATA DA BANCA PROFILO
Regulatory Filings Classification · 1% confidence The document is a press release (“Comunicato Stampa”) announcing Arterra Bioscience’s participation in an investor conference and stating that the institutional presentation will be made available on its website. It does not contain financial results (so not an Earnings Release), detailed presentation content (so not an Investor Presentation), nor a formal published report (so not a Report Publication Announcement). It is therefore a general regulatory announcement that falls into the fallback “Regulatory Filings” category.
2026-04-07 Italian
Arterra - Il Consiglio di Amministrazione ha approvato il progetto di bilancio di esercizio al 31 Dicembre 2025
Earnings Release Classification · 1% confidence The document is a corporate press release (“Comunicato Stampa”) announcing that the Board approved the draft financial statements for the year ended 31 December 2025, summarising key financial metrics (revenues, EBITDA, net profit, PFN), outlining dividend proposal, and convening the ordinary shareholders’ meeting. It is not the full Annual Report (10-K) or audited report itself (no complete notes or auditor’s opinion), but rather an initial announcement of full-year results. Therefore, it best fits the definition of an Earnings Release (ER). FY 2025
2026-03-27 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.